Sanofi American Depositary Receipt logo

Sanofi American Depositary Receipt (SNY)

Market Closed
5 Dec, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
49. 53
+0.63
+1.29%
Pre Market
$
49. 99
+0.46 +0.93%
122.7B Market Cap
- P/E Ratio
8.15% Div Yield
2,342,411 Volume
- Eps
$ 48.9
Previous Close
Day Range
49.2 49.73
Year Range
44.62 60.12
Want to track SNY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 52 days

Summary

SNY closed Friday higher at $49.53, an increase of 1.29% from Thursday's close, completing a monthly decrease of -1.41% or $0.71. Over the past 12 months, SNY stock gained 2.5%.
SNY pays dividends to its shareholders, with the most recent payment made on Jun 06, 2024. The next estimated payment will be in 6 months ago on Jun 06, 2025 for a total of $2.03691.
The last earnings report, released on Oct 24, 2025, exceeded the consensus estimates by 0.07%. On average, the company has surpassed earnings expectations by 0.02%, based on the last three reports. The next scheduled earnings report is due on Jan 29, 2026.
Sanofi American Depositary Receipt has completed 2 stock splits, with the recent split occurring on Sep 30, 2013.
The company's stock is traded on 8 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

SNY Chart

Similar

Amgen Inc.
$ 329.89
-3.02%
Gilead Sciences Inc.
$ 121.22
-1.14%
Vertex Pharmaceuticals Inc.
$ 455.48
-0.41%
Regeneron Pharmaceuticals, Inc.
$ 718.36
-0.61%
Alnylam Pharmaceuticals Inc.
$ 458.12
-1.55%
SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria

SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria

Sanofi/Regeneron's Dupixent wins EU nod for chronic spontaneous urticaria, marking its seventh approved indication across inflammatory diseases in the EU.

Zacks | 1 week ago
Bristol Myers, Sanofi sued by Texas over Plavix

Bristol Myers, Sanofi sued by Texas over Plavix

Texas Attorney General Ken Paxton sued Bristol Myers Squibb and Sanofi , accusing the drugmakers of failing to disclose that Plavix, which is used to prevent blood clots, does not work effectively for many patients.

Reuters | 2 weeks ago
Sanofi: Is Dupixent Too Successful?

Sanofi: Is Dupixent Too Successful?

Sanofi delivered strong Q3 results despite currency headwinds. The company's dependence on Dupixent is increasing. A broad immunology pipeline and the Blueprint Medicines acquisition should help address the issue.

Seekingalpha | 1 month ago

Sanofi American Depositary Receipt (SNY) FAQ

What is the stock price today?

The current price is $49.53.

On which exchange is it traded?

Sanofi American Depositary Receipt is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is SNY.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 8.15%.

What is its market cap?

As of today, the market cap is 122.7B.

What is the earnings per share?

The EPS is 0.82.

When is the next earnings date?

The next earnings report will release on Jan 29, 2026.

Has Sanofi American Depositary Receipt ever had a stock split?

Sanofi American Depositary Receipt had 2 splits and the recent split was on Sep 30, 2013.

Sanofi American Depositary Receipt Profile

Pharmaceuticals Industry
Healthcare Sector
Paul Hudson CEO
NASDAQ (NGS) Exchange
80105N105 CUSIP
FR Country
82,878 Employees
- Last Dividend
30 Sep 2013 Last Split
- IPO Date

Overview

Sanofi is a global leader in healthcare, deeply engaged in the journey of pushing the boundaries of medicine to improve health outcomes across the world. Founded in 1973 and headquartered in Paris, France, the company has evolved its name from Sanofi-Aventis to Sanofi in May 2011, marking a milestone in its expansive history. With a robust presence in the United States, Europe, and various international markets, Sanofi undertakes the research, development, manufacture, and marketing of therapeutic solutions through a comprehensive portfolio segmented into Pharmaceuticals, Vaccines, and Consumer Healthcare. The company's dedication to innovation is underscored by its collaborations, including a notable one with GlaxoSmithKline for a Covid-19 vaccine and a research venture with Stanford University School of Medicine focused on immunology and inflammation. Furthermore, Sanofi's partnership with Prellis Biologics, Inc., showcases its commitment to exploring new horizons in healthcare solutions.

Products and Services

  • Specialty Care Products: Sanofi delivers cutting-edge treatments in various therapeutic areas. This includes human monoclonal antibodies, treatments for multiple sclerosis, neurology, inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders. These products underline Sanofi's commitment to addressing complex health conditions with innovative solutions.
  • Diabetes and Cardiovascular Products: The company offers a range of medicines for diabetes care, showcasing its role in battling this global epidemic. Additionally, it provides products for cardiovascular health, emphasizing the importance of managing heart-related conditions.
  • Vaccines: With an emphasis on public health, Sanofi supplies vaccines for poliomyelitis, pertussis, and Hib for children; influenza, adult boosters, meningitis, and vaccines for travel and endemic diseases for adults, highlighting its role in preventing infectious diseases across all age groups.
  • Consumer Healthcare: Beyond prescription medicines, Sanofi extends its healthcare solutions to over-the-counter products. This includes allergy relief, cough and cold therapies, pain management, liver care, products promoting physical and mental wellness, probiotics, digestive health, and nutritional products. The range also features daily body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and powders for eczema, catering to a wide array of consumer health needs.
  • Pharmaceutical Products and Vaccines in Development: Sanofi is actively involved in the development of new pharmaceuticals and vaccines, pointing to a future of continued innovation and enhanced healthcare solutions. This commitment to research and development ensures Sanofi remains at the forefront of addressing emerging health challenges.

Contact Information

Address: 54, Rue La BoEtie
Phone: 33 1 53 77 40 00